• Kia unveils PV7, the second model in its dedicated, all-electric Platform Beyond Vehicle (PBV) lineup, designed to deliver greater space, flexibility and capability for commercial operations and passenger transport
• PV7 Passenger combines flexible seating and long-distance comfort, while PV7 Cargo offers high load capacity, low loading height and business-focused practicality
• PBV-dedicated E-GMP.S architecture combines 800V charging and long-range capability and a scalable drivetrain portfolio
• PV7 evolves Kia's PBV design DNA through bold, upright proportions and user-focused details that maximize space, accessibility and everyday usability
• Flexible seating, conversion capability, connected services and fleet management solutions support diverse customer requirements
• Kia to showcase the PV7 and wider PBV lineup to public at IAA Transportation 2026 from September 15–20

HANNOVER, Germany, Sept. 14, 2026 /PRNewswire/ -- Kia Corporation (Kia) today unveiled the Kia PV7 at IAA Transportation 2026 in Hannover, Germany. The second model in Kia's dedicated, all-electric Platform Beyond Vehicle (PBV) lineup, the PV7 expands the brand's offering in the light commercial vehicle (LCV) segment.

Available in Cargo and Passenger variants, the PV7 combines electric performance, flexible interior space and connected technology to support a wide range of business and mobility applications. Built on Kia's PBV-dedicated E-GMP.S architecture, it features a flat-floor design that maximizes interior space and flexibility, along with productivity-focused solutions that help customers achieve greater productivity in their day-to-day operations and drive stronger business outcomes. Kia will launch the PV7 in Korea and Europe in 2027, with additional derivatives and markets to follow.

"The PV7 marks the next step in our journey toward personalized mobility, building on the foundation established by the PV5," said Ho Sung Song, President and CEO at Kia. "By bringing together hardware developed for specific applications, business-tailored software and dedicated PBV services, the PV7 goes beyond the vehicle itself to deliver a complete business solution that helps customers achieve greater productivity, flexibility and long-term value."

How does the PV7 advance Kia's PBV strategy?

Building on the foundation established by the PV5, named the 2026 International Van of the Year, the PV7 expands the scale and scope of Kia's PBV offering. Its larger dimensions and broader application potential enable Kia to serve a wider range of customer needs, from fleet, logistics and shuttle operations to small- and medium-sized businesses and personal mobility. Kia's PV7 strategy is built around three business-focused pillars: hardware, software and service.

At the hardware level, the PV7 is built on Kia's PBV-dedicated E-GMP.S architecture, leveraging Kia's proven EV expertise and Flexible Body System^[1] to support a wide range of body styles, derivatives and conversion models tailored to diverse operational needs. This comprehensive lineup enables the PV7 to serve as a business-tailored tool, providing customers with the flexibility to adapt the vehicle to their specific operational requirements.

At the software level, Kia provides the Kia Business Solutions Portal, which supports fleet management, charging, maintenance and daily operations. Standardized Fleet Management System (FMS) and connected vehicle data APIs tailored to customers' operational needs help improve fleet visibility and support more efficient day-to-day operations. 

In addition, Kia offers dedicated Uptime services that support vehicle availability through real-time monitoring, predictive diagnostics and proactive maintenance management. Together, these connected solutions are designed to reduce operational disruption and support Kia's commitment to service excellence.

Kia's business-tailored service is centered on PBV-dedicated services designed to provide tailored support across diverse business operations, lower total cost of ownership and support higher vehicle uptime. Kia plans to expand the PV7 lineup to 23 variants following its 2027 launch, with the PV9 set to follow in 2029, further broadening the brand's PBV lineup and mobility solutions.

"The PV7 has been developed to give customers the flexibility to adapt as needs evolve," said Sangdae Kim, Executive Vice President and Head of Kia's PBV Business Division. "As a business-tailored tool engineered to deliver best-in-class EV performance, data-driven solutions, and total service excellence, it will enable customers to improve work efficiency, enhance productivity, and create greater value throughout the business lifecycle."

-ENDS-

Visit Kia Global Newsroom for more Kia content

For more information, visit the Kia Global Brand Site or Kia Global Newsroom. Follow our Kia Global Newsroom Instagram channel @kia.globalnews and LinkedIn account @Kia Global News

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-pv7-expands-all-electric-pbv-lineup-with-greater-capacity-and-flexibility-302877451.html

Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.

Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.

Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.

Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.